Zentralblatt fur Gynakologie · 1997
[Rate of proliferation as a prognostic criterion in endometrial carcinoma--an immunohistochemical analysis with the monoclonal antibody KI-S1].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Backe J, Gassel A M, Müller T, Schön S, Kaesemann H
Аннотация
In a subset of 183 primarily operative treated patients of 300 patients with endometrial carcinoma an analysis of histological tumor type (n = 142), myometrial invasion (n = 115), stage (n = 114), immunohistochemically detected steroid receptor status, histologic grading (n = 152) and growth fraction, detected by immunohistochemical determination of antibody Ki-S1 (n = 130), was performed. The mean follow up was 9.1 years. By univariate analysis, age, myometrial invasion (< = 3/>3 mm), expression of steroid receptor, FIGO-stage, histologic grading and growth fraction were found to influence the overall survival rate significantly. Cox multivariate regression showed age, FIGO-stage and growth fraction to be independent predictors of overall survival. With respect to survival univariate analysis revealed progesterone receptor status, FIGO-stage, histologic grading and growth fraction as prognostic factors. By multivariate analysis FIGO-stage, histologic grading and growth fraction were found to be independent prognostic factors for survival. Multivariate and univariate analysis exhibited FIGO-stage, histologic grading and growth fraction rate to be independent predictors of a disease-free survival. Immunohistochemically detected growth fraction seems to be useful as an additional prognostic factor in endometrial cancer.
Предметные рубрики MeSH
AdenocarcinomaAdultAgedAged, 80 and overAntibodies, MonoclonalBiomarkers, TumorCarcinoma, Squamous CellCell DivisionEndometrial NeoplasmsEndometriumFemaleHumansImmunoenzyme TechniquesMiddle AgedMyometriumNeoplasm InvasivenessNeoplasm StagingPrognosisReceptors, EstrogenReceptors, ProgesteroneSurvival Rate